Carla Ferrise
Nurse Practitioner · Farmington Hills, MINPI 1194025395
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,415 of the $40,594 with a category attached, or 65.1%. Novo Nordisk accounts for 79.7% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2022 at $16,779 and has fallen 86.7% since, to $2,229 in 2025. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 508 payments — averaging $79.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$32K
- Lilly USA, LLC$1K
- Mannkind Corporation$940
- Sanofi-aventis U.S. LLC$816
- Amgen$667
- Abbott$570
- plus $4K from 38 others
Across 13 payments — averaging $112.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$26,41565%
- Travel & lodging$3,0738%
- Food & beverage$10,73026%
- Education$510%
- Other$3251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,594 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 325 | $577,194 |
| TrulicityDulaglutide | 260 | $457,402 |
| JardianceEmpagliflozin | 262 | $337,925 |
| MounjaroTirzepatide | 86 | $142,373 |
| Tresiba Flextouch U-200Insulin Degludec | 90 | $142,066 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 54 | $130,319 |
| FarxigaDapagliflozin Propanediol | 93 | $120,073 |
| AfrezzaInsulin Regular, Human | 15 | $79,346 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $70,988 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $64,339 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $56,654 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 273 | $56,212 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $53,563 |
| JanuviaSitagliptin Phosphate | 45 | $51,547 |
| Novolog FlexpenInsulin Aspart | 127 | $51,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $32,343 | $726,647391 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,011 | $612,486377 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Glyxambi | $229 | $398,946333 claims |
| AstraZenecaFarxiga | $181 | $120,07393 claims |
| Mannkind CorporationAfrezza | $940 | $79,34615 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $816 | $59,59749 claims |
| MerckJanuvia, Steglatro | $164 | $55,67057 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $123 | $3,549289 claims |
| AbbVieSynthroid | $240 | $3,01523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Farmington Hills
- Davida KrugerDetroit$739K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
- Debra DegraffGrand Rapids$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.